Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Renal Cell Adenocarcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableEnded earlyNCT04831138
What this trial is testing

Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Metastatic Renal Cell Carcinoma

Who this might be right for
Renal Cell Carcinoma
University of Texas Southwestern Medical Center 6
Testing effectiveness (Phase 2)UnknownNCT00873236
What this trial is testing

MRI Scans of Blood Vessel Changes Caused by Bevacizumab Alone or Given Together With Interferon Alpha-2a in Treating Patients With Stage III or Stage IV Kidney Cancer

Who this might be right for
Kidney Cancer
Mount Vernon Cancer Centre at Mount Vernon Hospital 30
Testing effectiveness (Phase 2)UnknownNCT05013099
What this trial is testing

Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies

Who this might be right for
MelanomaMerkel Cell Carcinoma, UnspecifiedRenal Cell Carcinoma+1 more
ImaginAb, Inc. 70
Not applicableStudy completedNCT06582849
What this trial is testing

Enhanced Assistance During Radiotherapy for Unmet Essential Needs

Who this might be right for
Bone CancerBrain CancerColorectal Cancer+24 more
Washington University School of Medicine 33
Not applicableStudy completedNCT05882747
What this trial is testing

Renal Cell Carcinoma Metastases to Pancreas

Who this might be right for
Surgery
Rigshospitalet, Denmark 25
Testing effectiveness (Phase 2)Study completedNCT02960906
What this trial is testing

A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer

Who this might be right for
Clear Cell Metastatic Renal Cell Carcinoma
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie 200
Not applicableNo Longer AvailableNCT00655252
What this trial is testing

Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy

Who this might be right for
Metastatic Renal Cell Cancer
Novartis Pharmaceuticals
Not applicableEnded earlyNCT03846128
What this trial is testing

Impact of Sunitinib Bioavailability on Toxicity and Treatment Efficacy in Patients Treated for Metastatic Renal Cancer

Who this might be right for
Metastatic Kidney Cancer
University Hospital, Rouen 6
Not applicableLooking for participantsNCT06751498
What this trial is testing

The Value of a Convolutional Neural Network-Based Renal Artery Perfusion Model in Predicting Renal Function After Partial Nephrectomy: A Prospective Study

Who this might be right for
Renal Cell Cancer
Shao Pengfei 300
Not applicableStudy completedNCT01550393
What this trial is testing

Biomarkers in Urine Samples From Patients With Wilms Tumor

Who this might be right for
Kidney Cancer
Children's Oncology Group 100
Not applicableEnded earlyNCT07117409
What this trial is testing

Retrospective Study on the Safety of Nivolumab in Patients With mRCC and Renal Failure

Who this might be right for
Metastatic Renal Cell Carcinoma
Azienda USL Reggio Emilia - IRCCS 81
Testing effectiveness (Phase 2)Study completedNCT03693612
What this trial is testing

GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

Who this might be right for
Neoplasms
GlaxoSmithKline 26
Not applicableWithdrawnNCT04941365
What this trial is testing

Quantifying Systemic Immunosuppression to Personalize Cancer Therapy

Who this might be right for
Metastatic MelanomaMetastatic Breast CancerAdvanced Renal Cell Carcinoma+3 more
Institut du Cancer de Montpellier - Val d'Aurelle
Testing effectiveness (Phase 2)Ended earlyNCT04088500
What this trial is testing

Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma

Who this might be right for
Renal Cell Carcinoma
Bristol-Myers Squibb 5
Not applicableUnknownNCT05135832
What this trial is testing

Patient Reported Outcomes by Patients With Metastatic Renal Cell Carcinoma

Who this might be right for
Metastatic Renal Cell CarcinomaKidney CancerKidney Neoplasm+3 more
Herlev and Gentofte Hospital 174
Testing effectiveness (Phase 2)Ended earlyNCT02669914
What this trial is testing

MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors

Who this might be right for
Non-Small Cell Lung CancerNonsmall Cell Lung CancerBreast Cancer+15 more
Washington University School of Medicine 4
Testing effectiveness (Phase 2)UnknownNCT01444807
What this trial is testing

Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases

Who this might be right for
Metastatic Renal Cell Carcinoma
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 132
Early research (Phase 1)Study completedNCT02406521
What this trial is testing

Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets

Who this might be right for
Metastatic Renal Cell Carcinoma
Dana-Farber Cancer Institute 30
Early research (Phase 1)UnknownNCT05420519
What this trial is testing

Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer

Who this might be right for
Metastatic TumorRenal Cell CarcinomaAdvanced Cancer
Chongqing Precision Biotech Co., Ltd 24
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06730932
What this trial is testing

A Prospective，Single Arm, Multicenter Clinical Study of BTLA Monoclonal Antibody JS004 (B/T Lymphocyte Attenuator Factor Monoclonal Antibody) in Combination With Toripalimab in Patients With Unresectable or Advanced Renal Cell Carcinoma Who Had Failed Previous Immunotherapy

Who this might be right for
Unresectable or Advanced Clear Cell Renal Cell Carcinoma That Has Progressed After Previous Immunotherapy
RenJi Hospital 31
Next Page